Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00681382
First received: May 19, 2008
Last updated: January 21, 2011
Last verified: January 2011

May 19, 2008
January 21, 2011
October 2006
April 2007   (final data collection date for primary outcome measure)
Patients perceptions about treatment of asthma, asthma medication and what are the most common triggers that cause exacerbations. [ Time Frame: Single occasion ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00681382 on ClinicalTrials.gov Archive Site
  • How patients react to the first signs of worsening of asthma i.e. how they use asthma medication during stable phase and asthma exacerbation [ Time Frame: Single occasion ] [ Designated as safety issue: No ]
  • How asthma affects everyday life [ Time Frame: Single occasion ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland
INSPIRE Asthma Patient Survey to Clarify the Use of Asthma Medication and Effects of Asthma in Everyday Life in Finland

This study was aimed at clarifying how the asthma medication is used in practice and how asthma affects everyday life. Total of 106 GPs were asked to recruit patients using inhaled steroid as maintenance treatment for asthma to take part in a telephone survey. Altogether 142 patients were interviewed.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Primary care clinic

Asthma
Not Provided
1
Asthma patients using inhaled steroids as maintenance treatment
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
142
April 2007
April 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed persistent asthma
  • regular use of inhaled steroids and concomitant medication

Exclusion Criteria:

  • never been diagnosed COPD
  • seasonal asthma
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00681382
NIS-RFI-SYM-2006/1
No
Klaus Tamminen - MC Medical Director, AstraZeneca
AstraZeneca
Not Provided
Study Director: Airi Puhakka AstraZeneca Finland
Principal Investigator: Jouni Hedman South Karelia Central Hospital, Finland
AstraZeneca
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP